Aidebis · Evidence-based safety and harm-reduction overview.
| Also known as | Aidebis |
| Category | Nootropic |
| chemical_family | Synthetic ubiquinone analog |
| developer | Takeda Pharmaceutical (Japan) |
| mechanism_distinction | Alternative electron transport, not CoQ10-dependent |
| US legal status | Not FDA-approved as drug; some formulations sold as dietary supplements in US but regulatory status is murky. Approved pharmaceutical outside US. |
Synthetic analog of CoQ10, proposed to enhance mitochondrial energy and act as neural antioxidant. Idebenone was designed to improve upon ubiquinone by increasing blood-brain barrier penetration and mitochondrial electron transport efficiency without CoQ10-dependent pathways.
Idebenone functions as an alternative electron acceptor in the electron transport chain, bypassing Complex I deficiencies. It enhances ATP production in mitochondria while providing free radical scavenging activity. Unlike CoQ10, it operates partially independent of normal ubiquinone-dependent pathways.
Developed in Japan in the 1980s by Takeda Pharmaceutical as a potential Alzheimer's and age-related cognitive decline treatment. Studied extensively in Japanese and European clinical trials. Marketed as Aidebis in some countries; never pursued major FDA approval pathway.
Clinical trials mostly from 1990s-2000s; moderate evidence in Alzheimer's and age-related cognitive decline. Mixed results and limited recent replication. Most robust data from early Alzheimer's disease trials; modern neurodegenerative disease research sparse.
Clinical trials used 90-360 mg daily, typically in three divided doses. Most common doses were 120-180 mg daily. Dietary supplement formulations range 30-150 mg per serving.
This is general research/context information, not medical advice or a recommended protocol.
Historically combined with other mitochondrial supporters (carnitine, NADH) and antioxidants in European clinical protocols, though formal studies lack. Modern protocols favor idebenone plus CoQ10 at lower doses rather than high-dose single agent.
CoQ10 ubiquinol (reduced form). Better-studied and widely available dietary supplement with antioxidant and mitochondrial support; more bioavailable than idebenone.
See our recommended pickIf you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.
Compare testing optionsIdebenone is a synthetic analog designed to be more bioavailable and cross the blood-brain barrier better than CoQ10, but evidence is mixed.
Early studies in Alzheimer's showed modest benefits; more recent rigorous trials are limited. Mixed results overall.
Combining them is possible but may compete for electron transport chain function; medical guidance is advisable.
Idebenone accepts electrons in the mitochondrial electron transport chain, allowing ATP production even when Complex I is impaired.
Idebenone was pursued because it was theorized to have better brain penetration and work independently of ubiquinone-dependent pathways.
Medical & legal disclaimer. This site is for informational and harm-reduction purposes only. It is not medical advice and is not a substitute for a licensed healthcare professional. The compounds discussed are largely not approved by the FDA for human use and many are sold strictly as research chemicals 'not for human consumption.' Nothing here is an endorsement to purchase, possess, or use any substance. Laws vary by jurisdiction. Always consult a qualified physician and follow the law where you live.
Some links on this page may be affiliate links. If you buy through them we may earn a commission at no extra cost to you. This never changes the safety information we publish.